stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Shares outstanding
NeoGenomics, Inc.'s shares outstanding at the end of fiscal 2025 was $128.1M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $128.6M. Over the past ten years it has ranged from $60.5M (fiscal 2015) to $128.1M (fiscal 2025) — the current reading is the highest in ten years. NeoGenomics, Inc. ranks 13th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $128.1M | 1.14% |
| FY2024 | $126.7M | 0.92% |
| FY2023 | $125.5M | 1.03% |
| FY2022 | $124.2M | 3.55% |
| FY2021 | $120.0M | 7.31% |
| FY2020 | $111.8M | 7.89% |
| FY2019 | $103.6M | 13.16% |
| FY2018 | $91.6M | 15.29% |
| FY2017 | $79.4M | 2.43% |
| FY2016 | $77.5M | 28.11% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $128.6M | (1.72%) |
| Jun 2026 | $130.8M | 1.29% |
| Mar 2026 | $129.2M | 0.83% |
| Dec 2025 | $128.1M | (0.24%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| OPK OPKO Health, Inc. compare | $746.5M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| NEO NeoGenomics, Inc. | $128.6M |
| PSNL Personalis, Inc. compare | $107.2M |
| VCYT Veracyte, Inc. compare | $82.8M |
| CDNA CareDx, Inc. compare | $55.0M |
| CSTL Castle Biosciences, Inc. compare | $30.6M |
| WGS GeneDx Holdings Corp. compare | $29.7M |
| FRNM Freenome, Inc compare | $2.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement